Skip to content

Procedural Framing and Epidural Steroid Injection Outcomes

PEACE Study: Psychophysical Enhancement to Augment Conservative and Epidural Steroid Injection Outcomes: A Multi-Center International Randomized Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07498140
Acronym
PEACE
Enrollment
210
Registered
2026-03-27
Start date
2026-03-30
Completion date
2028-06-30
Last updated
2026-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbosacral Radiculopathy

Keywords

Back pain, Lumbar radiculopathy, Epidural steroid injection, Placebo effect, Sciatica, Positive framing

Brief summary

Back pain is the leading cause of disability and military medical boards across the globe. Epidural steroid injections (ESI) are the most commonly performed pain procedure in the world. There is strong evidence that the placebo effect for all pain treatments, including ESI, is greater than the intrinsic effect. The placebo effect is highly dependent on a patient's 'expectations', and therefore how the procedure is framed. This study aims to compare ESI when the procedure is framed very positively- as is often done in clinical practice vs. more neutrally (which is less commonly done in clinical practice but consistent with evidence). The placebo effect is also stronger for procedures than medications. The evidence on the benefits of ESI is highly dependent on whether it is compiled by interventional doctors who perform the procedure or non-interventional researchers. In order to determine how 'framing' a treatment affects pain outcomes, the investigative team will conduct a 3-arm randomized trial comparing positive framing of ESI, neutral framing of ESI, and medications, in patients with lumbosacral radiculopathy.

Detailed description

Two hundred and ten eligible individuals will be randomized in blocks of 10 in a 2:2:1 ratio to receive positive framing for ESI (treatment group), neutral framing for ESI (control group), or pharmacological therapy and instructions to exercise (active control group), respectively. There will suballocation based on whether the patient has unilateral or bilateral pain (i.e., whether the participant would receive a transforaminal ESI or an interlaminar ESI, respectively). This is because there may be differences in outcomes (transforaminal injections for unilateral pain may be more effective than an interlaminar injection for bilateral pain), as well as possible differences in side effects. For the 84 individuals randomized to the study group (positive framing of ESI), the investigators will provide 5 slides with bullet points and images outlining peer-reviewed studies, reviews and guidelines on ESI that present the treatment in a more positive light (consistent with the views of most people who perform ESIs), but still consistent with evidence. These slides will contain references to high-quality articles and there will be an investigator present to answer questions. There is a very wide range in how a procedure is presented to patients, and this framework is consistent with how ESI are presented to patients by pain practitioners from all over the world. This material is all publicly available but has been compiled in presentation form. For the 84 individuals in the ESI control group, the investigative team will provide a 1-slide overview on ESI that is slightly less optimistic, consistent with how many non-pain-physicians view ESI including that the evidence for surgery reduction is questionable. For the 42 individuals in the active control group who will receive a first-line medication for neuropathic and non-structured instructions to exercise, the investigators will provide a 1-side overview that presents the raw, neutral facts on adjuvants for sciatica (some guidelines recommend them, others do not, but some recommend a trial of conservative care for back pain before interventions; there are no medications across the globe approved for lumbosacral radiculopathy).

Interventions

BEHAVIORALBehavioral manipulation of ESI expectations

5-slide summary of ESI portrayed in a positive light, accompanied by a study investigator.

OTHERNo behavioral manipulation of ESI expectations

1-slide summary of ESI portrayed in a neutral light.

OTHERNo behavioral manipulation of pharmacotherapy expectations

1-slide summary of medications for neuropathic pain portrayed in a neutral light.

Sponsors

Northwestern University
Lead SponsorOTHER
Phramongkutklao College of Medicine and Hospital
CollaboratorOTHER
Ramathibodi Hospital
CollaboratorOTHER
Walter Reed National Military Medical Center
CollaboratorFED
First Lviv Medical Union
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Age \> 18 * Lumbosacral radicular pain based on history and physical exam (e.g. pain radiating into one or both lower extremities, sensory loss, muscle weakness, positive straight leg raising test etc.) * Duration of pain \>6 weeks * NRS leg pain score \>/= 4 (or if 3/10, greater or equal to back pain \& worst leg pain is \>/=4) * MRI evidence of spinal pathology consistent with symptoms * Candidates for ESI and pharmacotherapy

Exclusion criteria

* Untreated coagulopathy * Previous spine surgery * No MRI or non-concordant MRI study * Leg pain \> 15 years duration * Epidural steroid injection within past 2 years * Signs or symptoms of cauda equina syndrome * Previous failed trials with gabapentin and pregabalin and tricyclic antidepressants and duloxetine * Allergic reactions to contrast dye prohibiting injection (e.g., tranforaminal ESI), gabapentinoids, tricyclic antidepressants or duloxetine, and contraindications to all of the above medications * Referrals from surgery for diagnostic injections for surgical evaluation * Serious medical (e.g. congestive heart failure) or psychiatric (untreated depression) condition that might preclude optimal outcome * Pregnancy * Inability to understand basic English

Design outcomes

Primary

MeasureTime frameDescription
Mean reduction in average leg pain4 weeksMean reduction in average leg pain on a 0-10 numerical rating pain scale over the past week. This is the study's primary endpoint. 0=no pain, 10= worst pain imaginable.

Secondary

MeasureTime frameDescription
Leg pain at restUp to 15 minutes after the procedureLeg pain at rest on a 0-10 verbal rating scale while in the recovery area. 0=no pain, 10= worst pain imaginable.
Leg pain with activityUp to 15 minutes after the procedureLeg pain with walking and bending on a 0-10 verbal rating scale while in the recovery area
Back pain at restUp to 15 minutes after the procedureBack pain at rest on a 0-10 verbal rating scale while in the recovery area
Back pain with activityUp to 15 minutes after the procedureBack pain with activity (walking, bending) on a 0-10 verbal rating scale while in the recovery area
Patient satisfactionUp to 15 minutes after the procedurePatient satisfaction with ESI on 1-5 Likert scale (1= very unsatisfied, 3= neutral, 5= very satisfied), recorded upon recovery area discharge
Average leg pain4 weeksAverage leg pain on a 0-10 numerical rating scale over the past week
Average back pain4 weeksAverage back pain on a 0-10 numerical rating scale over the past week
Worst leg pain4 weeksWorst leg pain on a 0-10 numerical rating scale over the past week
Worst back pain4 weeksWorst back pain on a 0-10 numerical rating scale over the past week
Oswestry Disability Index (ODI)4 weeksOswestry Disability Index on 0-50 scale (converted to %), with higher scores indicating greater back pain-related disability
Hospital Anxiety and Depression Scale (HADS)4 weeksAnxiety and Depression scores (0-21 for each subscale), with higher scores indicating greater disease burden (anxiety and depression)
Athens Insomnia Scale4 weeksMeasure of insomnia scored from 0-24, with higher scores indicating greater sleep dysfunction
Analgesic medication reduction4 weeks\>20% reduction in opioids or cessation of non-opioid analgesic
Patient global impression of change (PGIC)4 weeksPatient satisfaction with ESI on 1-7 Likert scale (1= no change, 3= a little better, 4= somewhat better 5= moderately better, 7= a great deal better)
Positive categorical outcome4 weeks\>/=30% reduction in average leg pain (or worst leg pain if average leg pain \</=4) with a PGIC \>/=4

Countries

Thailand, Ukraine, United States

Contacts

CONTACTSteven P Cohen, MD
steven.cohen@northwestern.edu312-695-2500
CONTACTJordan Wood, BS
Jordan.Wood1@northwestern.edu312-695-2500
PRINCIPAL_INVESTIGATORSteven P Cohen, MD

Northwestern University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 19, 2026